Shefali Sood, MD
Ophthalmology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sood’s office to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
$41,108
Pharmacies billed $41,108 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 290) in 2024. At or below the middle of the specialty; the typical student in an organized health care education/training program clinician is at 0%.
159 generic and 131 brand-name prescriptions · $41,108 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Alphagan P | 20 | $9,064 | $453 |
| Rhopressa | 22 | $7,109 | $323 |
| Rocklatan | 18 | $5,920 | $329 |
| Brimonidine | 29 | $3,450 | $119 |
| Dorzolamide-Timolol | 12 | $868 | $72 |
See all 9 drugs
| Alphagan P | 20 | $9,064 | $453 |
| Rhopressa | 22 | $7,109 | $323 |
| Rocklatan | 18 | $5,920 | $329 |
| Brimonidine | 29 | $3,450 | $119 |
| Dorzolamide-Timolol | 12 | $868 | $72 |
| Prednisolone Acetate | 16 | $691 | $43 |
| Latanoprost | 73 | $437 | $6 |
| Dorzolamide-Timolol | 39 | $335 | $9 |
| Dorzolamide | 13 | $295 | $23 |
Year by year
| 2024 | 290 | 79 | 0% (0) | 45% | $41,108 |
| 2023 | 114 | 59 | None | 32% | $7,395 |
| 2022 | 42 | 15 | 0% (0) | 43% | $5,991 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Prednisolone Acetate | 18 | $1,000 | $56 |
| Latanoprost | 26 | $492 | $19 |
| Dorzolamide-Timolol | 14 | $225 | $16 |
Money from drug and device companies
$398 in 2025
A payment is not proof that care is biased.
| Alcon Vision | Tryptyr | $222 | 5 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $136 | 1 payment
|
| Astellas Pharma Global Development | Izervay | $22 | 1 payment
|
| Abbvie | Ozurdex | $18 | 1 payment
|
See all 8 published payments
| Alcon Vision | Meals · 2025-11-19 | Clareon | $24 |
| Astellas Pharma Global Development | Meals · 2025-10-23 | Izervay | $22 |
| Alcon Vision | Meals · 2025-10-06 | Tryptyr | $115 |
| Alcon Vision | Meals · 2025-08-20 | Clareon | $24 |
| Alcon Vision | Meals · 2025-05-27 | Centurion | $32 |
| Tarsus Pharmaceuticals | Meals · 2025-05-12 | Xdemvy | $136 |
| Alcon Vision | Meals · 2025-04-09 | Centurion | $26 |
| Abbvie | Meals · 2025-01-13 | Ozurdex | $18 |
Professional record
- NPI
- 1558003558
- Trained
- New York University School of Medicine, 2022
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2022-04-11
- NPI last updated
- 2026-07-07
- NPI record certified
- 2026-07-07
This is when the NPI record was last certified, not a medical board exam.